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97evidence that protein aggregates can spread in a “prion-like” fashion, we reasoned that a small pop-
ulation of brain cells producing such “prion-like” particles due to a postzygotic acquired mutation
would be sufficient to trigger the disease. Deep DNA sequencing technology should in principle allow
the detection of such mosaics.
Methods: To detect the somatic mutations of genes causing AD present in a small number of cells,
we developed a targeted deep sequencing approach to scrutinize the genomic loci of APP, PSEN1,
and PSEN2 genes in DNA extracted from the entorhinal cortex, one of the brain regions showing
the earliest signs of AD pathology. We also included the analysis of the MAPT gene because muta-
tions may promote tangle formation. We validated candidate mutations with an independent targeted
ultradeep amplicon sequencing technique.
Results: We demonstrate that our approach can detect single-nucleotide mosaic variants with a 1%
allele frequency and copy number mosaic variants present in as few as 10% of cells. We screened 72
AD and 58 control brain samples and identified three mosaic variants with low allelic frequency
(w1%): two novel MAPT variants in sporadic AD patients and a known PSEN2 variant in a Braak
II control subject. Moreover, we detected both novel and known pathogenic nonmosaic heterozygous
variants in PSEN1 and PSEN2 in this cohort of sporadic AD patients.
Conclusion: Our results show that mosaic mutations with low allelic frequencies in AD-relevant
genes can be detected in brain-derived DNA, but larger samples need to be investigated before a
more definitive conclusion with regard to the pathogenicity of such mosaics can be made.
 2015 The Alzheimer’s Association. Published by Elsevier Inc. All rights reserved.98
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1091. Introduction
The concepts of somatic disease-causing mutations and
of mosaic genomic heterogeneity are well known in the eti-
ology of cancer [1–3]. Recently, several studies have
highlighted the role of such acquired mutations asights reserved.
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203pathogenic drivers for neurodevelopmental diseases [4–7].
The possibility that mosaic mutations contribute to
neurodegenerative diseases should also be considered [8–
11]. Indeed, neurons accumulate a wide spectrum
of somatic mutations, in the forms of single nucleotide
variants (SNVs), insertion/deletions (indels), retrotrans-
positions, copy number variants (CNVs), and whole-
chromosomal aneuploidies [4,5,12–14]. Although the
mutation rate of human cells varies for different kind of
mutations and for different tissues, a rate of 1 ! 10210 de
novo point mutations per base per cell cycle is a
reasonable estimate [15,16], implying approximately one
new mutation per cell division. The brain contains w1011
neurons and about a similar number of nonneuronal cells
[17], thus it is easily conceivable that pathogenic mutations
may arise de novo in a mosaic fashion during its ontogenesis.
Depending on the time point of the mutation appearance in
the cell lineage tree descending from the zygote, the
sequencing of DNA isolated from blood may only excep-
tionally detect such mutation [18] (Fig. 1). This explains
why this potentially important phenomenon has not been
systematically investigated for Alzheimer’s disease (AD).
Most AD patients are sporadic (SAD), i.e., character-
ized by a late onset and unclear familial inheritance.
The biochemical and clinical features of SAD resemble
those of familial AD (FAD), which is characterized by
a clear autosomal dominant inheritance of causative mu-
tations in mainly three genes (APP, PSEN1, and PSEN2)
[19,20]. Growing evidence that protein aggregates of Ab
or Tau (encoded by MAPT gene) can spread in the brainFig. 1. Somatic mutations and hypothesis of pathology spread in sporadic Alzhe
human body (B), this is the typical case of a familial AD patient. In case of muta
for such mutation, with cells either carrying the mutation (orange) or not (white). D
genetic mosaics can be either extensive (C), with mutant cells appearing in several o
tissue. Our working hypothesis is that some sporadic AD patients are focal mosaic
(Ab) and/or tau aggregates produced locally as consequence of the mosaic mutati
brain areas in a “prion-like” fashion, thus leading to full blown AD.
FLA 5.2.0 DTD  JALZ1971_proofand act as local initiators of further aggregation of normal
proteins in a “prion-like” fashion [21–25], provides a
mechanistic framework to understand how somatic
mutations in the brain could spark neurodegenerative
disease. De novo mosaic mutations of AD-relevant genes
would create a nidus of mutant cells mixed between
normal cells that would continuously produce and release
proaggregating proteins. Such aggregates could act as
seeds for further protein aggregation at sites distal from
their origin (Fig. 1).
Detection of low-grade mosaic mutations has been
hindered by the low sensitivity of classical Sanger
sequencing, which allows the detection of mosaic muta-
tions only with an allelic frequency of at least 20%
[26]. Recent attempts to identify mosaic pathogenic mu-
tations in Parkinson’s disease used high-resolution
melting analysis, which allows the detection of mutations
with 5% to 10% allelic frequency [11]. Here, we deep
sequenced DNA libraries enriched for AD-relevant genes
to achieve high sequencing depth, followed by an ampli-
con ultradeep sequencing validation: this approach
enabled the detection of mosaic SNVs having an allelic
fraction as low as 1%.2. Materials and methods
2.1. Samples
Small blocks (w100 mg) of entorhinal cortex were
obtained from Lille NeuroBank (BB-0033-00030) andimer’s disease (AD). An inherited mutation will be carried by all cells of a
Q19tions arising in a postzygotic stage, an individual will be a genetic mosaic
epending on the developmental time point of the appearance of the mutation,
rgans/tissues, or focal (D), whenmutant cells are localized in a single organ/
s for mutations in AD-relevant genes appearing in brain cells. Amyloid beta
on can then spread (red arrows in (D) and seed further aggregation in other
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This study was approved by the KU Leuven ethical commis-
sion. Plaque burden and Tau tangles were scored according
to CERAD parameters and to Braak staging, respectively.
Brain samples showing a Braak stage of up to III were
included in the “non-AD” group. The “non-AD” group con-
sisted mainly of subjects showing mild ageing processes,
consistent with the respective age of death.
2.2. DNA isolation
Genomic DNA (gDNA) was isolated from 50 to 100 mg
of tissue. Briefly, frozen tissue was mechanically crushed
and digested overnight with protease K. Digested samples
were treated with RNase A (Qiagen, Venlo, The
Netherlands). Subsequently, DNAwas isolated with phenol:-
chloroform:isoamyl alcohol, washed with chloroform:i-
soamyl alcohol and precipitated with cold 100%. The
DNA pellet was washed with 70% ethanol, air-dried, and re-
suspended in TE buffer. Double-stranded DNA content was
assayed using Qubit dsDNABR assay with a Qubit 2.0 Fluo-
rometer (both from Life Technologies, Gent, Belgium).
DNA isolation and quantification were carried out in a labo-
ratory separated from the sites where sequencing libraries
were prepared, to minimize the contamination of tissue sam-
ples and DNA stocks.
2.3. Custom library enrichment for region of interest
A SeqCap EZ Choice Library (NimbleGen, Roche Nim-
bleGen, Madison, WI) was designed to target the genomic
regions of APP (chr21:27242859-27553138), PSEN1
(chr14:73593141-73700399), PSEN2 (chr1:227048271-
227093804), and MAPT (chr17:43961646-44115799),
including 10 kb both upstream and downstream of each
locus. For MAPT, we also included regions specific for the
alternate assembly of chr17_ctg5_hap1 (chr17_ctg5_
hap1:762280-895830). All genomic coordinates refer to
the human genome build hg19.
2.4. Library preparation, enrichment, and deep
sequencing
For library preparation, 3 mg of gDNA (corresponding to
w461,538 copies of diploid genomes, based on an average
human diploid cell DNA content of 6.5 pg) was sheared by
sonication and indexed libraries were prepared using the
TruSeq DNA kit (Illumina, San Diego, CA). Pools of 10 li-
braries were enriched with the SeqCap probeset described
previously, following manufacturer’s recommendations.
Each enriched-pool was paired end (2! 100 bp) sequenced
using a lane of HiSeq2000 (Illumina). To ensure the correct
assignment of sequences to each of the pooled samples, in-
dexes had at least three different nucleotides between each
other, and sequence demultiplexing was allowed a
maximum of one mismatch in the index. Library prepara-
tion, enrichment, and sequencing were carried out in theFLA 5.2.0 DTD  JALZ1971_proofUZ Genomics Core facility, following strict rules for pre-
and post-PCR rooms.
2.5. Data analysis
Raw sequencing data (FASTQ files) were aligned to the
hg19 reference genome using BWA (version 0.6.2) [27]. Re-
gions of interest (ROIs) were extracted from the SAM Qfiles
using samtools (version 0.1.18) [28]; sequences were then
realigned around indels and base qualities were recalibrated
using GATK (version 2.0-39-gd91f72) [29]. Variant calls
were made using Varscan 2.3.2 [30] on single-sample
samtools mpileup files and annotated using Annovar
(version 2012May25) [31]. Variants are reported accord-
ing to the following transcripts: NM_000484 (APP),
NM_001123066, and NM_005910 (MAPT), NM_000021
(PSEN1), NM_000447 (PSEN2). CNVs were analyzed us-
ing Varscan and the DNAcopy (version 1.36.0) R package.
Data were analyzed using the free statistical software R
(http://www.r-project.org/).
2.6. Amplicon deep sequencing
Primers were designed using Primer3 (http://bioinfo.ut.
ee/primer3-0.4.0/), excluding primers overlapping the posi-
tions of known SNPs Q(as obtained by UCSC genome
browser, track common SNPs [138]). Primers were synthe-
sized by IDT (Leuven, Belgium). Amplicons were prepared
using HotStar HiFidelity Polymerase kit (Qiagen) following
the manufacturer’s recommendations. PCR reactions were
carried out for 25 cycles, using 25 ng of template DNA (cor-
responding to w3846 copies of diploid genomes). Ampli-
cons were analyzed on 2% agarose gels stained with
GelGreen (Biotium, Hayward, CA) and specific bands
were cut and purified using QIAquick gel extraction kit (Qia-
gen). Purified amplicons were quantified with Qubit dsDNA
HS assay (Invitrogen) and pooled. Individual pools were
used to prepare indexed sequencing libraries and sequenced
on a MiSeq (Illumina) using paired-end 300 bp reads.
FASTQ files were aligned to the hg19 reference genome us-
ing BWA-MEM algorithm of BWA Q, mutation calling was
performed using samtools mpileup and Varscan. To mini-
mize risks of contamination, amplicons were prepared and
sequenced in different laboratories from those where DNA
had been isolated and where HiSeq libraries were prepared.
2.7. Sanger sequencing
Primer design and amplicon preparation were perfor-
med as described previously. The VIB Genetic Service Fa-
cility (http://www.vibgeneticservicefacility.be/) performed
Sanger sequencing of the purified amplicons.
2.8. Quantitative PCR
The copy number of APP locus was assessed by quantita-
tive PCR using predesigned TaqMan Copy number assays 28 April 2015  5:25 pm  ce
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Applied Biosystems (Foster City, CA). qPCR reactions
were assembled in 96-well plates according to
manufacturer’s instructions using TaqMan Genotyping Mas-
ter Mix (Applied Biosystems) and 20 ng of template DNA/
reaction. Assays were run in technical quadruplicates on a
Lightcycler LC480 (Roche Diagnostics, Basel,
Switzerland).424
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4753. Results
3.1. Targeted deep-sequencing allows the detection of
mosaic mutations with 1% allele frequency
The detection of low-grade mosaic variants is a major
methodological challenge, critically relying on high
sequencing depth to correctly call a variant over a large
number of wild-type sequences and to discriminate the
variant from noise due to sequencing errors and read mis-
alignments [32]. To maximize the coverage across our
ROIs we enriched our libraries using a custom-designed
probe set for the genomic loci of PSEN1, PSEN2, APP,
and MAPT genes, including 10 kb up- and downstream
for each locus, to gather enough information for both
SNV and CNV calling. Available solutions to read mis-
alignments are local realignment (with tools such as
GATK IndelRealigner [29]) and base quality recalibration
(with algorithms such as BAQ recalculation implemented
by samtools mpileup [33]). Sequencing errors can be esti-
mated using several computational methods, here we use
Varscan 2.0 [30] as it was found to excel in low-grade
mosaic mutations calling [32].
To establish our workflow and benchmark our method,
we analyzed a series of “synthetic mosaics” prepared by
mixing gDNA of fibroblasts carrying a heterozygous
APP E682K mutation (C . T chr21:27269905) with
gDNA carrying a homozygous wild-type allele
(Supplementary Fig. 1A). As expected, on average more
than half of the total reads were aligned to the ROI
(52.3% 6 5.9%, avg 6 standard deviation or SD), allow-
ing for high sequencing depth (average coverage
2735X 6 429X SD; average 82.6% 6 3.9% SD of ROI
covered at 1000!). To maximize the sensitivity and
specificity of mosaic SNV calling, we tested several pipe-
lines combining the modules of GATK and mpileup BAQ
with Varscan (Fig. 2). The position of the pilot APP muta-
tion was highly covered in all “synthetic mosaic” samples
(3572 6 759 reads, avg 6 SD) and could be readily iden-
tified by several calling pipelines down to the 1% “syn-
thetic mosaic” (actual observed mutant allele frequency
of 0.94%–0.96%), whereas the 0.5% “synthetic mosaic”
could not be distinguished from the 0% sample
(Fig. 2A). A high base-quality cut-off [30] in Varscan in
combination with BAQ recalculation failed to call the het-
erozygous mutation. To evaluate the sensitivity of our
method, we considered all the heterozygous SNVs in theFLA 5.2.0 DTD  JALZ1971_prooforiginal APP mutant DNA sample which were absent in
the admixed one (therefore following the same behavior
as the pilot mutation in the mixed samples, Supple-
mentary Fig. 1A) and which were sequenced at
1000!. Sensitivity and accuracy, as measures of the
fraction of mosaic variants called and the correctness of
the observed mutant allele frequency, respectively, were
strikingly different across the pipelines, the best perform-
ing being GATK-BAQ-V15 and noGATK-BAQ-V15
(Fig. 2B). Both pipelines were able to detect all the syn-
thetic mosaic variants at 1% (n 5 38 and 36, respectively)
at high accuracy (observed mutant allele frequency
1.6% 6 0.7% SD) (Fig. 2B). The accuracy for the “syn-
thetic mosaic” variants at 0.5% was not satisfactory, as
they did not recover all the variants (for a variant to be
called in a “synthetic mosaic” sample, its observed allele
frequency had to be higher than the average observed
allele frequency in the 0% sample, for the same pipeline)
(Fig. 2B, right panel).
To evaluate specificity, we reasoned that genomic
positions sequenced at very high depth (1000!) and dis-
playing no mutant bases in both original DNAs should
show no mutant bases in the mixed samples as well.
Mutations called at these positions in the mixtures
would then constitute false positive (FP) calls. With all the
tested pipelines we identified a very high number of FP calls
having very low allelic frequencies, as expected
(Supplementary Table 1, Supplementary Fig. 2 and
Fig. 2C). In general, the number of FP rose steeply below
the 1% mark, explaining why the 0.5% “synthetic mosaic”
could not be distinguished from background errors
(Fig. 2A and B). BAQ recalculation greatly reduced the
number of FP, in particular those few with allelic frequency
greater than 1% (Fig. 2C, compare left and middle panels).
Taken together, these results show that the GATK-BAQ-
V15 analysis pipeline is able to detect the “synthetic mosaic”
variants with an alternate allele frequency as low as 1%, with
a manageable trade-off of FP calls.3.2. Identification and validation of low-grade mosaic
variants in brain
We next analyzed gDNA isolated from entorhinal
cortex samples of a cohort of 72 SAD and 58 non-
AD control subjects (demographics are provided in
Supplementary Fig. 3 and Supplementary Table 2).
As expected, capture efficiency varied between
different experiments (41% 6 20% SD of the total se-
quences aligned to ROI) but the average sequencing
depth across our ROI was in all instances high enough
for the detection of low-grade mosaic mutations
(2153X 6 985X, avg 6 SD; 85.3% 6 8.6% avg 6
SD of ROI covered at 1000!). We determined all
variants using the established variant calling pipeline,
and selected for further analysis the nonsynonymous
variants with an observed allelic frequency 0.9% 28 April 2015  5:25 pm  ce
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Fig. 2. Deep sequencing of capture-enriched libraries allows the detection of 1% mosaic mutations and MiSeq targeted amplicon sequencing allows the detec-
tion of mosaic variants with 0.5% mutant allele frequency. (A) We tested several combinations of software to call mutations in the sequenced libraries, i.e., the
GATK indel-realigner/base-recalibration (GATK), the mpileup with (BAQ) and without (noBAQ) BAQ recalculation and the Varscan quality filter (V15 and
V30 for base quality thresholds of 15 and 30, respectively). We used a defined series of serial dilutions of DNA bearing an APP single nucleotide variant
(SNV) (C . T at position chr21:27269905) and wild-type DNA. For each combination of software tools (pipeline), the observed mutant allele frequency of
the pilot APP SNV is plotted against the expected mutant allele frequency. (B) To further assess sensitivity and accuracy of the pipelines, we analyzed the
SNVs called heterozygous in the APP mutant DNA and wild type in the admixed DNA. For each dilution sample (indicated by the expected mutant allele fre-
quency on the x axis), we plot the observedmutant allele frequency of the SNVs analyzed by each pipeline (n5 38 for GATK-BAQ-V15, n5 8 for GATK-BAQ-
V30, n5 41 for GATK-noBAQ-V15, n5 29 for GATK-noBAQ-V30, n5 36 for noGATK-BAQ-V15, n5 12 for noGATK-BAQ-V30). Boxes extend from the
25th to the 75th percentile with whiskers extending to 10th and 90th percentile, data points outside the whiskers are represented with dots. The horizontal line in
each box represents the median. The plot has been divided in two panels to allow better readability. (C) To evaluate the specificity of each calling pipeline, we
plotted the sum of the false positive (FP) SNV calls detected in the five dilution samples (number of SNVs, y axis) for each bin (0.1%) of mutant allele frequency
(ALT freq, x axis); axes are zoomed to 10% (x axis) and 100 (y axis). The full graphs are reported in Supplementary Fig. 2. (D) To validate candidate mosaic
mutations identified by HiSeq sequencing of capture-enriched libraries, we used amplicon sequencing on a MiSeq. This latter method was benchmarked by
mixing the genomic DNA of four individuals with mutations at positions chr1:227083249 (PSEN2 gene), chr14:73653568 (PSEN1 gene), chr17:44067341
(MAPT gene), and chr21:27269905 (APP gene), respectively, wild-type DNA to prepare templates with different amounts of mutant alleles (25%, 10%,
5%, 1%, and 0.5%). Parental DNAs (50% and 0% mutant alleles, respectively) and mixed samples were PCR amplified and sequenced on a MiSeq. For
each dilution (n5 4 for dilution step), the observed mutant allele frequency is plotted as a box plot (same as in (B)). In each case the observed frequency closely
matches the expected frequency (dotted lines). Mutations present at 0.5% mutant allelic frequency could be called against the background.
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597and with a coverage 900. Based on the analysis of the
“synthetic mosaic” samples, an allelic frequency cut-
off of 0.9% provides very high sensitivity (.97%)
with an acceptable trade-off of FP calls (4.2 6 3.6,
average 6 SD, FP calls per sample of 130,744 poten-
tial positions; Supplementary Fig. 4). We also note
that using a minimum coverage of 900! instead of
1000! leads to one extra FP calls at a 0.9% allelic
frequency cut-off (4.2 6 3.6 FPs/sample versusFLA 5.2.0 DTD  JALZ1971_proof3.2 6 2.8 FPs/sample, respectively). Excluding a
series of known nonpathogenic MAPT polymorphisms
(P202L, Q230R, D285N, V289A, R370W, Y441H,
S447P), we retained a total of 128 variants. Of these,
107 had a mutant allele frequency compatible with a
mosaic nature (0.9%  frequency , 40%), whereas
the remainder had allele frequencies between 40%
and 60% and were therefore inferred to be heterozy-
gous (Supplementary Table 3 and Fig. 3). 28 April 2015  5:25 pm  ce
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Fig. 3. Mosaic and heterozygous nonmosaic variants found. We illustrate the positions of mosaic mutations (purple dots) and of novel mutations (blue dots)
found in the present study in relation to previously described pathogenic mutations (red dots) and known nonpathogenic variants (green dots) in PSEN1 (A),
PSEN2 (B), APP (C), and Tau (D). Mutations found in this study are named, mosaic ones are in bold. Numbered blue boxes in (A) and (B) represent
transmembrane domains of PSEN2, green boxes in (D) represent the microtubule binding domains of Tau. The blue, red, and green triangles in (C) indicate
b-, a-, and g-secretase cleavage sites, respectively.
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702By extrapolating the number of FP calls per sample
counted in our pilot experiment to the exonic regions
captured in these experiments (18,836 nucleotides), we ex-
pected 0.1 to 1.1 FP calls per sample. Thus we anticipated
betweenw12 andw145 FP calls in the analysis of the full
cohort. Therefore, to validate candidate mosaic variants,
we applied an independent amplicon ultradeep resequenc-
ing approach. Amplicons were sequenced on an Illumina
MiSeq to very high depth (12,455X to 324,885X depend-Table 1
Mosaic mutations found in our cohort
Subject Group Gene Mut rsID Notes Familiarit
BBN_9943 AD MAPT Q124K NOVEL No
BBN_9959 AD MAPT S735A
(S400A)
NOVEL None
recorde
BBN_16242 CT PSEN2 S130L rs63750197 Known None
recorde
NOTE. For each of the three validated mosaic mutations, we report the informat
and the information on the mutation (amino acid change, nucleotide change, genom
enriched library and the one observed with MiSeq sequencing of the targeted ampli
by Polyphen2). Mutation MAPT S735A (Tau-G numbering) is equivalent to MAP
FLA 5.2.0 DTD  JALZ1971_proofing on the amplicon, on average 111,485X 6 81,033X
SD) and analyzed with the GATK-BAQ-V15 pipeline
(Supplementary Table 3). To assess the sensitivity and ac-
curacy of this approach, we diluted gDNA of four individ-
uals bearing a different heterozygous mutation confirmed
by Sanger sequencing with wild-type gDNA, covering a
wide range of mutant allele frequencies (Fig. 2D). In all
cases, the observed mutant allele frequencies closely
matched the expected ones (Pearson r 5 0.996,y Variant
ALT
frequency
HiSeq
ALT
frequency
MiSeq MAF Q16Polyphen2
C . A chr17:44055803 1.1 1.0 n.a. Probably
damaging
d
T . G chr17:44101409 1.0 0.7 n.a. Probably
damaging
d
C . T chr1:227073271 5.7 1.6 .0.1 Possibly
damaging
ion on the mutation bearing subject (diagnostic group, family history of AD)
ic position, alternate allele frequency observed with HiSeq sequencing of the
con, MAF in the population (%) according to dbSNP and the effect predicted
T S400A (Tau-F numbering, 441 amino acid isoform).
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834Fig. 2D). Importantly, mutations with frequencies as low
as 0.5% could be readily called against background signal
(observed mutant allele frequencies of 0.58% 6 0.12 (avg
6 SD) for variants expected to be 0.5% versus
0.05% 6 0.03 (avg 6 SD) when 0% was expected,
Fig. 2D), highlighting the superb sensitivity and accuracy
of the validation assay.
Only three out of the 107 candidate variants were
confirmed in the validation assay (Table 1 and Fig. 3).
We considered a variant to be validated if its observed
mutant allele frequency was above the sensitivity of
detection of MiSeq, estimated to be 0.5% from Fig. 2D.
Subject BBN_9943, who died at 90 years old diagnosed
with AD at Braak stage VI and CERAD plaque score
C, showed a novel MAPT Q124K mutation present at
1.0% allelic frequency (concordant with the observed
1.1% frequency of the HiSeq sequencing). A control sub-
ject, BBN_16242, who died at 90 years old was diag-
nosed with mild AD-type changes (modified Braak
stage II) and mild amyloid angiopathy, and showed a
known PSEN2 S130L mutation present at 1.6% allelic
frequency (in contrast to the 5.7% observed alternate
allele frequency reported by HiSeq sequencing). Subject
BBN_9959, an AD patient with an apparent age of onset
at 85 years and deceased at 91 years, showed a novel
MAPT S735A (S400A in the Tau-F isoform) present at
0.7% allele frequency (compared with a 1.0% frequency
observed by HiSeq sequencing).
The candidate mosaic C . T variant at
chr1:227073271 (PSEN2 S130L mutation) discovered in
13 different subjects in the initial screen, was found to
be a FP call in 12 of them following validation. Contam-
ination from the sample carrying the heterozygous
PSEN2 S130L variant is unlikely, as this sample and
those carrying the candidate variants were prepared far
apart in time and sequenced in different sequencing
runs. More conclusively, three nearby heterozygous vari-
ants in the heterozygous S130L carrier (allele frequencies
of 46.14%, 45.42%, and 46.71%, respectively) were not
found with compatible allele frequencies in the mosaic
S130L carrier (below the defined limit of 0.9% for the
detection of mosaic variants in HiSeq sequences for the
first two and 99.5%, for the last one). Thus the detection
of this particular mosaic variant cannot be explained by
contamination with the DNA stock or sequencing library
from the heterozygous sample. These results indicate that
our targeted deep sequencing method is able to identify
candidate mosaic variants but with a high cost of false
positives. Amplicon ultradeep resequencing is therefore
absolutely necessary for validation.835
836
837
838
839
840
8413.3. Validation of heterozygous variants confirms their
likely germline nature
From the initial targeted deep sequencing, we also
identified 21 heterozygous variants (Table 2). Four vari-FLA 5.2.0 DTD  JALZ1971_proofants are known risk factors (PSEN1 E318G, MAPT
V224G, MAPT S427F and MAPT A469T) [34,35] and
one is nonpathogenic (MAPT IVS10 1 29) [36]. More-
over, two APP mutations (E246K and A479S) are located
outside the Ab region and are unlikely pathogenic. All re-
maining variants were validated by classical Sanger
sequencing and further investigated in other tissues when
possible, in an effort to clarify their germline or mosaic
nature.
For one subject, carrying PSEN2 A258T, DNA
extracted from blood cells was available, which allowed
unequivocal confirmation of the germline nature of the
variant. In all the other instances, only DNA from other
brain areas was available; here Sanger sequencing analysis
showed that these variants were present at heterozygous
frequency and are therefore likely germline. Four of
such variants, three found in AD subjects with no family
history (MAPT A90V, PSEN2 V101M, and PSEN2
L238F) and one in a control subject (MAPT P4T), are
novel. The remaining five variants (PSEN1 H163R,
PSEN2 R62C, PSEN2 R62H, PSEN2 S130L, and
PSEN2 D439A) have been previously described in associ-
ation with FAD; all of them except the latter were found in
SAD patients.3.4. Targeted deep sequencing allows the detection of
mosaic CNVs present in as low as 10% of cells
To test the sensitivity and specificity of our method for
identifying mosaic CNVs, we analyzed a set of “synthetic
CNV mosaic” samples obtained by mixing DNA isolated
from amniocytes of a trisomy 21 (T21) fetus with DNA
from euploid fibroblasts (75%, 50%, 10%, 5%, 1%, and
0.5% T21 DNA, respectively, Supplementary Fig. 1B), tak-
ing advantage of the fact that the APP locus is on chromo-
some 21.
Data analysis made use of the ratio of normalized
sequencing depth (on a log scale, LogR) and of the fre-
quency of the SNP alternate allele (B allele frequency,
BAF), which are well-established data sources used for
CNV analyses with SNP arrays [37]. In the 100% T21
DNA, trisomy 21 could be readily detected by analyzing
the LogR data (Fig. 4A). In addition, the BAF data for this
sample show SNPs with allele frequencies of w66% and
w33%, as expected [38] (Fig. 4B). In contrast, both LogR
and BAF demonstrated normal values for PSEN2, PSEN1,
and MAPT in the 100% T21 sample, consistent with the
diploid nature of these loci (Supplementary Fig. 5), thus con-
firming the accuracy of the method. LogR analysis was
furthermore able to identify decreasing grades of mosaicism,
down to 10%, across the APP locus (Fig. 4A), confirmed by
BAF data analysis (Fig. 4B). As a validation, we tested a
qPCR-based CNV detection method with three different
commercially available Taqman CNVassays; the sensitivity
limit was 25% T21 DNA (Fig. 4C). Thus, we conclude that
the enriched library—deep sequencing method and data 28 April 2015  5:25 pm  ce
Table 2
Heterozygous variants found in our cohort
Subject Group Gene Mut rsID Notes Familiarity Variant
ALT freque y
HiSeq MAF Polyphen2 Other tissues
C08-10048 AD MAPT A90V NOVEL No C . T chr17:44051799 45.7 n.a. Benign n.a.
BBN_10196 AD PSEN2 V101M NOVEL No G . A chr1:227071565 43.4 n.a. Probably damaging cer
BBN_9967 AD PSEN2 L238F NOVEL No C . T chr1:227076675 53.5 n.a. Probably damaging cer
BBN_3761 AD PSEN2 R62C rs150400387 Known Brother had AD C . T chr1:227071448 55.3 .0.1 Possibly damaging cer
C09-20305 AD PSEN1 H163R rs63750590 Known No A . G chr14:73653568 49.4 NA Possibly damaging hippo, cer
BBN_9975 AD PSEN2 R62H rs58973334 Known No G . A chr1:227071449 45.7 1.8 Benign cer
BBN_9975 AD APP E246K rs147485129 Outside of Ab region
outside of Ab region
No C . T chr21:27394285 45.8 NA Possibly damaging
C06-25448 AD PSEN2 S130L rs63750197 Known No C . T chr1:227073271 46.7 .0.1 Possibly damaging hippo
C08-19292 CT MAPT P4T NOVEL No C . A chr17:44039713 39.8 n.a. Probably damaging cer
BBN_16281 CT APP A479S rs143794560 Outside of Ab region
outside of Ab region
No C . A chr21:27347406 44.4 NA Benign cer
BBN_16213 CT PSEN2 D439A rs63750110 Known No A . C chr1:227083249 43.0 NA Probably damaging cer
UK82 CT PSEN2 A258T rs148238688 No G . A chr1:227076735 52.2 NA Probably damaging blood
BBN_10197 AD MAPT IVS10 1 29 rs63751443 Not pathogenic None recorded G . A chr17:44087797 48.8 NA NA
C08-31992 AD MAPT IVS10 1 29 rs63751443 Not pathogenic None recorded G . A chr17:44087797 46.3 NA NA
BBN_9967 AD PSEN1 E318G rs362373 Not pathogenic No A . G chr14:73673178 53.7 0.9 Benign
BBN_18399 CT PSEN1 E318G rs362373 Not pathogenic None recorded A . G chr14:73673178 49.1 0.9 Benign
BBN_9952 AD MAPT V224G rs141120474 Possible risk factor None recorded T . G chr17:44060841 41.0 .0.1 Possibly damaging
C09-20305 AD MAPT A469T rs143624519 Possible risk factor No G . A chr17:44068850 46.7 0.2 Benign
BBN_9959 AD MAPT S427F rs143956882 Possible risk factor None recorded C . T chr17:44067341 44.3 .0.1 Probably damaging
C08-07965 CT MAPT V224G rs141120474 Possible Q18risk factor None recorded T . G chr17:44060841 42.4 .0.1 Possibly damaging
C06-29159 CT MAPT S427F rs143956882 Possible risk factor None recorded C . T chr17:44067341 52.5 .0.1 Probably damaging
NOTE. For each of the 21 validated heterozygous variants (excluding known nonpathogenicMAPT polymorphisms), we report the information on the sub ct (diagnostic group, family history of AD) and the
information on the variant (amino acid change, nucleotide change, genomic position, alternate allele frequency observed with HiSeq sequencing, MAF in th population (%) according to dbSNP, and the effect
predicted by Polyphen2). Each variant was validated by Sanger sequencing in entorhinal cortex. For novel and known pathogenic variants, when available, w analyzed also other tissues (cer, cerebellum; hippo,
hippocampus; n.a., not available), in every case the variant was confirmed as heterozygous.
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Fig. 4. Deep sequencing of capture-enriched libraries allows the detection of 10% mosaic copy number variants (CNVs). A series of mixtures of DNA from a
trisomy 21 (T21) subject and from an euploid subject was analyzed to assess the lower limit of mosaic CNV detection. For each sample in the series (indicated
with colored bars), we report the normalized sequencing depth compared with the diploid control (LogR, A) and the B-allele frequency (BAF, B), calculated for
all positions of the captured region. The region presented on the x axis in both (A) and (B) corresponds to the captured APP locus (chr21:27242859-27553138).
Detection of mosaic CNVs was also performed by qPCR using three different probe sets (C). The calculated copy number of the APP gene for each sample is
reported for each probe set used and as an average of the signal obtained from the three probes for each sample. Asterisks denote statistical significant differences
versus the euploid sample (***P , .0001, **P , .001).
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1067analysis with the LogR method is the most sensitive method
to detect mosaic CNVs.
We analyzed accordingly our sequencing data, but no
CNVs of APP, PSEN1, PSEN2, orMAPTwere found. These
results indicate that the brain samples analyzed had more
than 90% of cells with the correct number of copies of these
genes.1068
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10854. Discussion
The potential contribution of somatic mutagenesis to
neurodegenerative disorders is increasingly recognized, but
little systematic study of this problem is available. Here,
we developed a methodology to analyze the presence of so-
matic mutations in known FAD genes in the brain. Using a
library enrichment-deep sequencing method we were able
to simultaneously interrogate the presence of mosaic
SNVs having a mutant allele frequency of 1% or more,
and mosaic CNVs present in as few as 10% of cells.
Although our method of library enrichment for a w600
kb ROI allows the simultaneous query of mosaic SNVs
and CNVs, based on the analysis of “synthetic mosaic” sam-
ples, it is clear that an allele frequency of 1% is an absolute
limit for mosaic SNVs detection at high sensitivity andFLA 5.2.0 DTD  JALZ1971_proofworkable specificity, due to increasingly FP calls.
Amplicon-based ultradeep resequencing with MiSeq was
sensitive enough to detect “synthetic mosaic” variants hav-
ing 0.5% mutant allele frequency and enabled the validation
of the putative variants. Further studies aimed at the detec-
tion of mosaic SNVs from a selected number of genes or
exons could thus be efficiently and cost-effectively per-
formed by deep-sequencing of PCR amplicons.
In this pilot study we identified three subjects, two
confirmed SAD and one Braak II “control”, with MiSeq-
validated mosaic variants. Two of these mosaic variants
were novel mutations of MAPT of unknown pathogenicity.
Bioinformatic prediction by Polyphen2 [39] indicates that
both MAPT Q124K and MAPT S400A (Tau-F numbering)
are “probably damaging”. MAPT Q124K is located in the
N-terminus of tau, whereas all known pathogenic tau muta-
tions concentrate in the microtubule-binding domains of the
C-terminus. In contrast, MAPT S400A is located in the C-
terminus close to a known pathogenic mutation (R406W).
AlthoughMAPT mutations do not cause familial AD, based
on the “double hit” cascade proposed for late onset AD [40]
we suggest the possibility that mosaic MAPT mutation may
co-operate with imbalances in Abmetabolism (for instance,
age-associated clearance problems with Ab). Given the 28 April 2015  5:25 pm  ce
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1207limited number of positive data, we cannot at the moment
make any statistical valid prediction about the possible asso-
ciation of such mutations with sporadic AD. The third
mosaic mutation, PSEN2 S130L, has been found before in
an AD family [41] and was also found in an SAD case
[42]. The pathogenicity of the PSEN2 S130L is disputed,
as it has been also found in two healthy individuals, however,
we note that in one instance the healthy subject was younger
than the age of onset for this particular mutation [41], and in
the second instance agewas not disclosed [42]. In our cohort,
we found the PSEN2 S130L variant as a nonmosaic hetero-
zygous mutation also in a SAD patient, who displayed an age
of onset at 66 years and died at 88 years of age. Finally, we
note that this mutation is predicted “possibly damaging” by
Polyphen2 and that it is located in the first loop of PSEN2,
next to three other pathogenic mutations (T122P, T122R,
E126K), however, pathogenicity of this mutation is clearly
not established [42,43].
Recent studies have highlighted that pathogenic variants
in AD-related genes can indeed be found in apparently spo-
radic AD cases, both early [44,45] and late onset [43].
Accordingly, in our study we found a relatively high number
of heterozygous mutations in brains from SAD patients.
Among these, six variants deserve some further discussion:
one confirmed pathogenic mutation (PSEN1 H163R [46]),
two variants of uncertain pathogenicity (PSEN2 R62C and
PSEN2 S130L), and three novel variants of unknown patho-
genicity (PSEN2 V101M, PSEN2 L238F, and MAPT
A90V). Both Polyphen2 and SIFT [47] predict that PSEN2
V101M and PSEN2 L238F are “probably damaging” and
“damaging” (SIFT scores 0 and 0.05, respectively), whereas
MAPTA90V is unlikely pathogenic (predicted “benign” by
Polyphen2). These six mutations were heterozygous in both
entorhinal cortex and cerebellum, indicating that they are
most likely constitutive variants rather than mosaics. Lack
of DNA samples from the parents prevented the investiga-
tion of whether the mutations occurred de novo in the germ-
line, but clinically the six cases were reported as apparent
sporadic. The parents of the patient bearing the pathogenic
PSEN1 H163R (rs63750590) [46,48] mutation died at 66
and 72 years, respectively, from heart problems and did
not show any signs of cognitive decline, whereas the
patient had an onset at 51 years and died at 56 years,
hinting that this mutation may have appeared de novo.
Further efficient study of mosaic pathogenic variants in
neurodegenerative disease requires that brain banks also
ascertain access to DNA from peripheral blood and, if
possible, to DNA from the close relatives.
We profited from our data set to try to uncover possible
mosaic APP duplications, as this is a known cause of FAD
[49]. Although in this pilot experiment no duplication of
the APP locus was found, we notice that our method allows
detecting a 10%mosaic gain and is therefore at least twice as
sensitive as quantitative PCR-based approaches.
Our study demonstrates that the analysis of brain samples
(as opposed to blood samples) could provide unexpectedFLA 5.2.0 DTD  JALZ1971_proofnew insights into the possibility that mosaics contribute to
the risk of developing AD. Here, we chose to study entorhi-
nal cortex, as this is the area where the first tau aggregates
appear over the course of AD pathology [50]. Because
mutant cells in this area may have been lost rather early in
the disease process, follow-up studies should also sample
other brain areas, to explore in a more systematic way the
phenomenon of mosaicisms for these genes. Moreover, it
will be important to study brain samples patients from
whom blood and possibly gDNA from both parents are avail-
able.
In conclusion, we show that variants in AD-related genes
with low allele frequencies can be detected in brain-derived
DNA. Although our data cannot formally prove the pathoge-
nicity of the mosaic variants identified, our work prompts for
follow-up studies in larger cohorts and using multiple sam-
pling of the same brain to understand whether mosaic muta-
tions might be causally linked to the disease. In fact, and a
priori, somatic genetic mosaicismmay prove to have a larger
effect on disease etiology than common susceptibility fac-
tors identified via genome-wide association studies. Our
work shows the feasibility of a larger and systematic study
to confirm or refute the hypothesis of mosaic mutations as
a cause of sporadic AD.Acknowledgments
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1329RESEARCH IN CONTEXT
1. Systematic review: Postzygotic acquired (somatic)
mutations in Alzheimer’s disease (AD)-relevant
genes could originate small group of brain cells pro-
ducing pathogenic amyloid beta (Ab) and Tau aggre-
gates which could spread over the brain, thus causing
sporadic AD. “Prion-like” spreading and seeding of
both Ab and Tau aggregates has been documented
in vitro and in vivo.
2. Interpretation: We describe a sensitive method to
detect and validate low-allele frequency mosaic
mutations. Moreover we report the discovery of pu-
tative mosaic mutations in brain-derived DNA of AD
patients and controls.
3. Future directions: The full extent of pathogenic
mosaic mutations in brain will be clear on the exam-
ination of multiple brain areas in wider cohorts of
subjects. Importantly, the concept of pathogenic
mosaic mutations can be explored also in other
neurodegenerative diseases, such as Parkinson’s dis-
ease.
References
[1] Watson IR, Takahashi K, Futreal PA, Chin L. Emerging patterns of
somatic mutations in cancer. Nat Rev Genet 2013;14:703–18.
[2] Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature
2009;458:719–24.
[3] Yates LR, Campbell PJ. Evolution of the cancer genome. Nat Rev
Genet 2014;13:795–806.
[4] Lee JH, Huynh M, Silhavy JL, Kim S, Dixon-Salazar T, Heiberg A,
et al. De novo somatic mutations in components of the PI3K-AKT3-
mTOR pathway cause hemimegalencephaly. Nat Genet 2012;
44:941–5.
[5] Poduri A, Evrony GD, Cai X, Elhosary PC, Beroukhim R,
Lehtinen MK, et al. Somatic activation of AKT3 causes hemispheric
developmental brain malformations. Neuron 2012;74:41–8.
[6] Jamuar SS, LamAT, Kircher M, D’Gama AM,Wang J, Barry BJ, et al.
Somatic mutations in cerebral cortical malformations. N Engl J Med
2014;371:733–43.
[7] Hu WF, Chahrour MH, Walsh CA. The diverse genetic landscape of
neurodevelopmental disorders. Annu Rev Genomics Hum Genet
2014;15:195–213.
[8] Frank SA. Evolution in health and medicine Sackler colloquium:
somatic evolutionary genomics: mutations during development cause
highly variable genetic mosaicismwith risk of cancer and neurodegen-
eration. Proc Natl Acad Sci U S A 2010;107(Suppl 1):1725–30.
[9] Pamphlett R. Somatic mutation: a cause of sporadic neurodegenerative
diseases? Med Hypotheses 2004;62:679–82.
[10] Poduri A, Evrony GD, Cai X, Walsh CA. Somatic mutation, genomic
variation, and neurological disease. Science 2013;341:1237758.
[11] Proukakis C, Houlden H, Schapira AH. Somatic alpha-synuclein mu-
tations in Parkinson’s disease: hypothesis and preliminary data. Mov
Disord 2013;28:705–12.FLA 5.2.0 DTD  JALZ1971_proof[12] Kingsbury MA, Friedman B, McConnell MJ, Rehen SK, Yang AH,
Kaushal D, et al. Aneuploid neurons are functionally active and inte-
grated into brain circuitry. Proc Natl Acad Sci U S A 2005;
102:6143–7.
[13] Muotri AR, Gage FH. Generation of neuronal variability and
complexity. Nature 2006;441:1087–93.
[14] Cai X, Evrony GD, Lehmann HS, Elhosary PC, Mehta BK, Poduri A,
et al. Single-cell, genome-wide sequencing identifies clonal somatic
copy-number variation in the human brain. Cell Rep 2014;8:1280–9.
[15] NussbaumR,McInnes R,Willard H. Thompson&Thompson genetics
in medicine. 7th Edition. Elsevier; 2007. Q
[16] Behjati S, HuchM, van Boxtel R, KarthausW,Wedge DC, Tamuri AU,
et al. Genome sequencing of normal cells reveals developmental line-
ages and mutational processes. Nature 2014;513:422–5.
[17] Azevedo FA, Carvalho LR, Grinberg LT, Farfel JM, Ferretti RE,
Leite RE, et al. Equal numbers of neuronal and nonneuronal cells
make the human brain an isometrically scaled-up primate brain. J
Comp Neurol 2009;513:532–41.
[18] Beck JA, Poulter M, Campbell TA, Uphill JB, Adamson G, Geddes JF,
et al. Somatic and germline mosaicism in sporadic early-onset Alz-
heimer’s disease. Hum Mol Genet 2004;13:1219–24.
[19] Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S,
Puel M, et al. Early-onset autosomal dominant Alzheimer disease:
prevalence, genetic heterogeneity, and mutation spectrum. Am
J Hum Genet 1999;65:664–70.
[20] Bertram L, Tanzi RE. The genetics of Alzheimer’s disease. Prog Mol
Biol Transl Sci 2012;107:79–100.
[21] Aguzzi A, Rajendran L. The transcellular spread of cytosolic amy-
loids, prions, and prionoids. Neuron 2009;64:783–90.
[22] Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA,
Schwarz RD, et al. Evidence for seeding of beta-amyloid by intracere-
bral infusion of Alzheimer brain extracts in beta-amyloid precursor
protein-transgenic mice. J Neurosci 2000;20:3606–11.
[23] Eisele YS, Obermuller U, Heilbronner G, Baumann F, Kaeser SA,
Wolburg H, et al. Peripherally applied Abeta-containing inoculates
induce cerebral beta-amyloidosis. Science 2010;330:980–2.
[24] Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S,
Probst A, et al. Transmission and spreading of tauopathy in transgenic
mouse brain. Nat Cell Biol 2009;11:909–13.
[25] de Calignon A, Polydoro M, Suarez-Calvet M, William C,
Adamowicz DH, Kopeikina KJ, et al. Propagation of tau pathology
in a model of early Alzheimer’s disease. Neuron 2012;73:685–97.
[26] Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD,
Eshleman JR, et al. Comparison of Sanger sequencing, pyrosequenc-
ing, and melting curve analysis for the detection of KRAS mutations:
diagnostic and clinical implications. J Mol Diagn 2010;12:425–32.
[27] Li H, Durbin R. Fast and accurate short read alignment with Burrows-
Wheeler transform. Bioinformatics 2009;25:1754–60.
[28] Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The
sequence alignment/map format and SAMtools. Bioinformatics 2009;
25:2078–9.
[29] McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K,
Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce
framework for analyzing next-generation DNA sequencing data.
Genome Res 2010;20:1297–303.
[30] Koboldt DC, Zhang Q, Larson DE, Shen D,McLellanMD, Lin L, et al.
VarScan 2: somatic mutation and copy number alteration discovery in
cancer by exome sequencing. Genome Res 2012;22:568–76.
[31] Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of
genetic variants from high-throughput sequencing data. Nucleic Acids
Res 2010;38:e164.
[32] Stead LF, Sutton KM, Taylor GR, Quirke P, Rabbitts P. Accurately
identifying low-allelic fraction variants in single samples with next-
generation sequencing: applications in tumor subclone resolution.
Hum Mutat 2013;34:1432–8.
[33] Li H. Improving SNP discovery by base alignment quality. Bioinfor-
matics 2011;27:1157–8. 28 April 2015  5:25 pm  ce
C.S. Frigerio et al. / Alzheimer’s & Dementia- (2015) 1-1212
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415[34] Benitez BA, Karch CM, Cai Y, Jin SC, Cooper B, Carrell D, et al. The
PSEN1, p.E318G variant increases the risk of Alzheimer’s disease in
APOE-epsilon4 carriers. PLoS Genet 2013;9:e1003685.
[35] Cruchaga C, Haller G, Chakraverty S,MayoK, Vallania FL,Mitra RD,
et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in
late-onset Alzheimer’s disease families. PLoS One 2012;7:e31039.
[36] D’Souza I, Poorkaj P, Hong M, Nochlin D, Lee VM, Bird TD, et al.
Missense and silent tau gene mutations cause frontotemporal dementia
with parkinsonism-chromosome 17 type, by affectingmultiple alterna-
tive RNA splicing regulatory elements. Proc Natl Acad Sci U S A
1999;96:5598–603.
[37] Biesecker LG, Spinner NB. A genomic view of mosaicism and human
disease. Nat Rev Genet 2013;14:307–20.
[38] Conlin LK, Thiel BD, Bonnemann CG, Medne L, Ernst LM,
Zackai EH, et al. Mechanisms of mosaicism, chimerism and uniparen-
tal disomy identified by single nucleotide polymorphism array anal-
ysis. Hum Mol Genet 2010;19:1263–75.
[39] Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A,
Bork P, et al. A method and server for predicting damaging missense
mutations. Nat Methods 2010;7:248–9.
[40] Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer’s
disease: a dual pathway hypothesis. Neuron 2008;60:534–42.
[41] Tedde A, Nacmias B, Ciantelli M, Forleo P, Cellini E, Bagnoli S, et al.
Identification of new presenilin gene mutations in early-onset familial
Alzheimer disease. Arch Neurol 2003;60:1541–4.
[42] Tomaino C, Bernardi L, Anfossi M, Costanzo A, Ferrise F, Gallo M,
et al. Presenilin 2 Ser130Leu mutation in a case of late-onset
“sporadic” Alzheimer’s disease. J Neurol 2007;254:391–3.FLA 5.2.0 DTD  JALZ1971_proof[43] Sassi C, Guerreiro R, Gibbs R, Ding J, Lupton MK, Troakes C,
et al. Investigating the role of rare coding variability in Mendelian
dementia genes (APP, PSEN1, PSEN2, GRN, MAPT, and PRNP)
in late-onset Alzheimer’s disease. Neurobiol Aging 2014;35:
2881.e1–6.
[44] Jin SC, Pastor P, Cooper B, Cervantes S, Benitez BA, Razquin C,
et al. Pooled-DNA sequencing identifies novel causative variants in
PSEN1, GRN and MAPT in a clinical early-onset and familial
Alzheimer’s disease Ibero-American cohort. Alzheimers Res Ther
2012;4:34.
[45] Sassi C, Guerreiro R, Gibbs R, Ding J, Lupton MK, Troakes C, et al.
Exome sequencing identifies 2 novel presenilin 1 mutations (p.L166V
and p.S230R) in British early-onset Alzheimer’s disease. Neurobiol
Aging 2014;35:2422.e13–6.
[46] Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G,
Ikeda M, et al. Cloning of a gene bearing missense mutations in
early-onset familial Alzheimer’s disease. Nature 1995;375:754–60.
[47] Ng PC, Henikoff S. Predicting deleterious amino acid substitutions.
Genome Res 2001;11:863–74.
[48] Campion D, Flaman JM, Brice A, Hannequin D, Dubois B, Martin C,
et al. Mutations of the presenilin I gene in families with early-onset
Alzheimer’s disease. Hum Mol Genet 1995;4:2373–7.
[49] Rovelet-Lecrux A, Frebourg T, Tuominen H, Majamaa K, Campion D,
Remes AM. APP locus duplication in a Finnish family with dementia
and intracerebral haemorrhage. J Neurol Neurosurg Psychiatry 2007;
78:1158–9.
[50] Braak H, Braak E. Neuropathological stageing of Alzheimer-related
changes. Acta Neuropathol 1991;82:239–59. 28 April 2015  5:26 pm  ce
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
